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study: RCP improves cardiovascular and renal function in acute
decompensated heart failure (ADHF) 
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Background: The RCP is a 14 French collapsable percutaneous cardiovascular support
device positioned in the descending part of the thoracic aorta via the femoral artery. A
10 patient first in man study demonstrated device safety and significant improvement
in renal function among high risk PCI patients. We now report haemodynamic and
renal efficacy in patients with ADHF.
Methods: Prospective non randomised study seeking to recruit 20 patients with ADHF
with a need for inotropic or mechanical circulatory support with: i) EF < 30% ii)
Cardiac index(CI) < 2.2 L / min / m2 Outcome measures included: 1) Cardiac index
(CI) 2) Pulmonary Capillary Wedge Pressure (PCWP) 3) Urine output / serum
creatinine 4) Vascular / device complications 5) 30 day mortality
Results: INTERIM ANALYSIS (n=12) The mean age of the study group was 64 years,
with a mean baseline creatinine of 193 umol/L, eGFR 38 ml/min. The intended RCP
treatment period was 24 hours. During RCP treatment there was a significant mean
reduction of PCWP at 4 hours of 17% (25 to 21 mmHg p=0.04). Mean CI increased at
12 hours by 11%, though not reaching significance (1.78 to 1.96 L/min/m2 p=0.08).
RCP insertion prompted substantial diuresis. Urine output tripled over the first 12 hours
compared to baseline (55 ml/hr vs 213 ml/hr p=0.03). This was associated with
significantly improved renal function, a 28% reduction in serum creatinine at 12 hours
(193 to 151 umol/L p=0.003), and a increase in eGFR from 38 ml/min to 50 ml/min
(p=0.0007). 2 patients previously refused cardiac transplantation were reassessed and
successfully transplanted within 9 months of RCP treatment on the basis of
demonstrable renal reversibility. There were no vascular or device complications. There
were 2 deaths at 30 days, one from multi-organ failure and sepsis, and one from
intractable heart failure - neither were device related.
Conclusion: RCP support in ADHF patients was associated with improved
haemodynamics, and an improvement in renal function. The Reitan Catheter Pump
may have a role in providing percutaneous cardiovascular and renal support in the
acutely decompensated cardiac patient, and may have a role in suggesting renal
reversibility in potential cardiac transplant patients. Further data will be reported at
recruitment completion.
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Background: Contrast-induced nephropathy (CIN) after percutaneous coronary
intervention (PCI) is associated with prolonged hospitalization and adverse clinical
outcomes. We sought to investigate whether biomarkers can be useful to predict the
occurrence of CIN after primary PCI for ST-segment elevation myocardial infarction
(STEMI).
Methods: A total of 26 inflammatory and thrombotic biomarkers were measured at
admission in 501 STEMI patients undergoing primary PCI enrolled in a formal
substudy of the HORIZONS-AMI trial, and analyzed at a central core laboratory. We
divided patients in tertiles based on biomarker levels and explored associations between
biomarkers and CIN defined as 1) a relative increase in serum creatinine of ≥25%, or
2) an absolute increase in serum creatinine of ≥0.5 mg/dL within 48 hours after primary
PCI.
Results: Information on CIN was available for 423 patients (84%). CIN defined as a
relative serum creatinine increase of ≥25% occurred in 60 patients (14.2%). High levels
of Brain Natriuretic Peptide (BNP), Pregnancy-Associated Plasma Protein A (PAPP-
A), von Willebrand factor (vWf), and heart-type fatty acid binding protein (hFABP)
were associated with this definition of CIN (Table 1). CIN defined as an absolute serum
creatinine increase of ≥0.5 mg/dl occurred in 15 patients (3.5%). Only Brain natriuretic
peptide (BNP) was associated with this definition of CIN (Table 1).
Conclusion: BNP, PAPP-A, vWF, and hFABP are potential biomarkers to predict CIN
in STEMI patients undergoing primary PCI. Larger prospective trials are warranted to
validate the utility of these biomarkers.
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Background: Renal impairment (RI) in patients undergoing percutaneous coronary
interventions (PCI) is associated with adverse prognosis. However, the impact of RI
on long-term clinical and angiographic outcomes among patients undergoing PCI with
the unrestricted use of drug-eluting stents (DES) is not well established.
Methods: Individual patient data were pooled for 5,011 patients from 3 all-comer trials
with the exclusive use of DES (SIRTAX - N=1,012, LEADERS - N=1,707,
RESOLUTE AC - N=2,292). Angiographic follow-up was available for 1,540 lesions.
Patients were stratified according to glomerular filtration rate (normal: ≥90 ml/min;
mild RI: 60-89 ml/min; moderate/severe RI: <60 ml/min). The primary endpoint was
the composite of cardiac death and myocardial infarction (MI). Angiographic endpoints
were in-stent late lumen loss (LL) and in-segment binary restenosis (BR).
Results: Through 2 years, patients with moderate/severe RI as compared to patients
with normal renal function had a higher risk of cardiac death or MI (adjusted OR=2.23,
95%CI 1.43-3.48, p<0.001), as well as cardiac death (adjusted OR=2.34, 95%CI 1.17-
4.67, p=0.02) and MI (adjusted OR=2.15, 95%CI 1.28-3.62, p<0.001). Patients with
mild RI as compared to patients with normal renal function had similar risk of cardiac
death or MI (adjusted OR=1.10, 95%CI 0.76-1.61, p=0.61). The risk of target-lesion
and target-vessel revascularization did not differ between the 3 groups, as did the risk
of definite or probable stent thrombosis. No differences were observed in terms of in-
stent LL and in-segment BR.
Conclusion: Patients with moderate/severe RI undergoing PCI with the unrestricted
use of DES have an increased risk of cardiac death and MI as compared to patients
with normal renal function during long-term follow-up. However, the efficacy of DES
is unaffected by renal function with similar rates of repeat revascularization and
angiographic outcomes regardless of renal impairment.
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Background: Chronic renal failure is known as one of the risk factors which predict
poor response to clopidogrel. However, there are few data regarding patients with
moderately decreased glomerular filtration rate (GFR).
Methods: In the CILON-T trial, 915 consecutive patients who underwent drug-eluting
stent implantation were randomized to receive either dual (DAT) or triple antiplatelet
therapy (TAT). We calculated GFR at the index admission and classified patients
according to GFR (Group 1: GFR≥60mL/min/1.73m2; Group 2:
30mL/min/1.73m2≤GFR<60mL/min/1.73m2). We compared P2Y12 reaction unit
(PRU), P2Y12 % and interval change of GFR between the two groups at six moths
follow up.
Results: 184 patients (20.1%) showed renal dysfunction
www.JACC.TCTAbstracts2011
B134 JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Contrast Nephropathy and Chronic Kidney Disease
P
O
S
T
E
R
S
